{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=21", "query": { "intervention": "CHANGE Study", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 6732, "total_pages": 674, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T08:40:15.279Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" }, { "nct_id": "NCT07673627", "title": "ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AChR-Ab Seropositive Generalized Myasthenia Gravis", "Myasthenia Gravis (MG)", "MG - Myasthenia Gravis", "gMG" ], "interventions": [ { "name": "Empasiprubart IV", "type": "BIOLOGICAL" }, { "name": "Placebo IV", "type": "OTHER" }, { "name": "Efgartigimod PH20 SC PFS", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "COMBINATION_PRODUCT" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-07-10", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 6, "location_summary": "Carlsbad, California • Miami, Florida • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Amherst", "state": "New York" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07673627" }, { "nct_id": "NCT07529405", "title": "A Study of VG712 in Patients With Mycosis Fungoides", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycosis Fungoides" ], "interventions": [ { "name": "VG712", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virogen Biotechnology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2026-07-30", "completion_date": "2032-12-30", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529405" }, { "nct_id": "NCT03518294", "title": "NASH Fitness Intervention in Thrombosis Trial (NASHFit)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Liver Diseases", "Blood Disorder", "Digestive System Disease" ], "interventions": [ { "name": "Aerobic Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2018-06-01", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2023-02-03", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518294" }, { "nct_id": "NCT01946594", "title": "Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fever" ], "interventions": [ { "name": "Acetaminophen", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "35 Months", "sex": "ALL", "summary": "12 Months to 35 Months" }, "enrollment_count": 41, "start_date": "2013-10", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946594" }, { "nct_id": "NCT04110288", "title": "VQI DELTA Paclitaxel Device Safety Analysis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Peripheral Vascular Disease" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Non-drug coated Device Treatment", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Lahey Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219483, "start_date": "2017-01-01", "completion_date": "2020-04-01", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Burlington, Massachusetts", "locations": [ { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04110288" }, { "nct_id": "NCT05440903", "title": "Mindfulness Training for Smoking Cessation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Headspace", "type": "BEHAVIORAL" }, { "name": "TEDTalk", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2020-12-08", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-09-07", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05440903" }, { "nct_id": "NCT05412927", "title": "AngelMed Guardian® System PMA Post Approval Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "PMA P150009 AngelMed Guardian® System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Angel Medical Systems", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 500, "start_date": "2022-09-07", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 18, "location_summary": "Glendale, Arizona • Mesa, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05412927" }, { "nct_id": "NCT03732261", "title": "Effects of Exercise and Yogurt on Bone Mineral Density and Immunological Factors in Human Milk: The MEEMA Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lactational Amenorrhea", "Body Weight Changes", "Bone Loss" ], "interventions": [ { "name": "Exercise and dietary", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "North Carolina Agriculture & Technical State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "25 Years to 40 Years · Female only" }, "enrollment_count": 13, "start_date": "2019-04-01", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2023-03-23", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 1, "location_summary": "Greensboro, North Carolina", "locations": [ { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732261" }, { "nct_id": "NCT06378866", "title": "Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Castration-Sensitive Prostate Carcinoma", "Recurrent Prostate Cancer", "Castration-resistant Prostate Cancer", "Biochemically Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Histrelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Triptorelin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Image-Guided Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 532, "start_date": "2024-06-03", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-26T08:40:15.279Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06378866" } ] }